4DMT (FDMT): P/S multiplikatori
Daromad koeffitsiyenti dinamikasi 4D Molecular Therapeutics (FDMT) kompaniyasining bozor qiymatini namoyish etadi, bunda 7.20 eng so'nggi metrika ko'rsatkichini ifodalaydi. Gen terapiyasi ishlab chiquvchisi barqaror talabga tayanadi, garchi uskunalar logistikasi va patent himoyasi geosiyosatga bog'liq bo'lib qolgan bo'lsa-da. Irsiy patologiyalarni davolash sektori no-tsiklikdir va biznes muvaffaqiyati vektorlarning klinik tasdiqlanishi hamda yetarli likvidlik rezervlariga asoslanadi.
4D Molecular Therapeutics kompaniyasining tahliliy kesimlari
- joriy narx va aksiyalarning prognoz qilingan qiymati:
- birja kapitallashuvi ma'lumotlari:
- balans bo'yicha xususiy kapital ma'lumotlari:
- qarz majburiyatlari va likvidlik statistikasi:
Umumiy qarzning xususiy kapitalga nisbati 4D Molecular Therapeutics|FDMT - Uzoq muddatli kreditlarning kapitalga nisbati|Qisqa muddatli qarzning kapitalga nisbati 4dmoleculartherapeutics.com|FDMT - Jamlangan qarz majburiyatlari|Balans kapitallashuviga qarzlar 4D Molecular Therapeutics Inc|FDMT - Uzoq muddatli qarz|Kompaniyaning qisqa muddatli qarzi 4D Molecular Therapeutics|Tezkor likvidlik koeffitsiyenti 4dmoleculartherapeutics.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
FDMT - Sof foyda|Kutilayotgan foyda 4D Molecular Therapeutics|FDMT - Kapitalizatsiyaning sof foydaga nisbati|Forvard P/E multiplikatori 4D Molecular Therapeutics, Inc.|FDMT - O‘sish sur’atiga tuzatilgan narx-foyda|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati koeffitsiyenti 4D Molecular Corp|FDMT - EBITDA operatsion foydasi|So'nggi 12 oy davomida bir aksiya uchun sof foyda 4D Molecular Therapeutics|FDMT - So'nggi to'rtta chorak uchun bir aksiya uchun foyda|Choraklik EPS foyda o'sishi 4dmoleculartherapeutics.com|FDMT - Bu yil bir aksiya uchun sof foydaning kutilayotgan o'sishi|Keyingi yil uchun foyda o'sishi prognozi 4D Molecular Therapeutics
- tushum va sotishdan olingan daromadlar ma'lumotlari:
Kompaniyaning asosiy tahlili:FDMT 4D Molecular Therapeutics
P/S koeffitsiyenti bir dollarlik daromadning bozor qiymatini belgilaydi va bu sof foyda mavjud bo'lmagan hollarda aktivning haddan tashqari qimmat baholanganligini baholash imkonini beradi. 4D Molecular Therapeutics (FDMT) kompaniyasining 7.20 miqdoridagi joriy P/S koeffitsiyentini tahlil qilib, investor 4D Molecular Therapeutics (FDMT) ning noyob vektor platformalari uchun premium to'lovni ko'radi, bu esa patent himoyasi tufayli raqobatchilar tomonidan narxlarga bo'lgan bosimni minimallashtiradi va biznesning yuqori fundamental baholanishini asoslaydi.
4D Molecular Therapeutics raqobatchilari tahlili
TEM (Tempus AI, Inc.) - Bozor kapitallashuvining daromadga nisbati|Qiagen Group - Kapitalizatsiyaning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati IONS|RGEN - Narxning daromadga nisbati|Narx/daromad koeffitsiyenti Avidity Biosciences RNA|CRSP: P/S multiplikatori|Kapitalizatsiya va daromad nisbati WGS|RARE (Ultragenyx Pharma) - P/S multiplikatori|P/S multiplikatori Beam Therapeutics Inc.|Narxning daromadga nisbati Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Kapitalizatsiya va daromad nisbati|10x Genomics Inc - Kapitalizatsiyaning daromadga nisbati|NTLA (Intellia Therapeutics, Inc.) - Narxning sotuvga nisbati|Stoke Corp - P/S multiplikatori|BLFS (BioLife) - Kapitalizatsiya va daromad nisbati|wavelifesciences.com (WVE) - Narxning daromadga nisbati|MAZE - Narx/daromad koeffitsiyenti|SION (Sionna Therapeutics, Inc.) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati Prime Medicine Corp (PRME)|P/S multiplikatori TSHA|P/S multiplikatori uniQure N.V. (QURE)|Narxning daromadga nisbati MeiraGTx Holdings plc MGTX|RGNX: Kapitalizatsiya va daromad nisbati|Solid Biosciences Inc - P/S multiplikatori|OCGN - P/S multiplikatori|PACB: P/S multiplikatori|BNTC - Narx/daromad koeffitsiyenti|Narxning daromadga nisbati Design Therapeutics, Inc.|RCKT: Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Bozor kapitallashuvining daromadga nisbati|P/S multiplikatori EDIT (Editas Medicine, Inc.)|P/S multiplikatori Silence Therapeutics Corp SLN|PRQR - Narxning daromadga nisbati|Narx/daromad koeffitsiyenti Codexis Inc CDXS|SGMO: P/S multiplikatori|Kapitalizatsiya va daromad nisbati NAUT|Narxning daromadga nisbati metagenomi.co|P/S multiplikatori Precision BioSciences Inc.|P/S multiplikatori GBIO|Boundless Bio, Inc. - Kapitalizatsiya va daromad nisbati|P/S multiplikatori XCUR (Exicure, Inc.)|Narx/daromad koeffitsiyenti Imunon, Inc. (IMNN)|PHIO - Narxning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati MBIO (mustangbio.com)|RNAZ: P/S multiplikatori|Kapitalizatsiya va daromad nisbati BNGO|APDN (Applied DNA Corp) - P/S multiplikatori|BLUE: Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati ImmunoPrecise (IPA)|OMGA - Sotuvga nisbatan narx|Narxning daromadga nisbati Singular Genomics OMIC|Bozor kapitallashuvining daromadga nisbati RGLS|Syros Pharmaceuticals, Inc. - P/S multiplikatori|Narx/daromad koeffitsiyenti Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Narxning daromadga nisbati|Unity Biotechnology, Inc - Bozor kapitallashuvining daromadga nisbati
